<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174524</url>
  </required_header>
  <id_info>
    <org_study_id>MedleyHGF</org_study_id>
    <nct_id>NCT01174524</nct_id>
  </id_info>
  <brief_title>Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme</brief_title>
  <official_title>Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Geral de Fortaleza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medley S∕A Indústria Farmacêutica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Geral de Fortaleza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether low-dose contraceptive pills are effective
      in the improvement of quality of life in patients in the different phases of menacme.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>eleven months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life in differents phases of menacme</measure>
    <time_frame>eleven months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Quality of Life</condition>
  <condition>Menopause</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>gestoden and ethinylestradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.
The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gestoden 60 mcg</intervention_name>
    <description>gestoden 60 mcg, once a day, administered in 24/4 regimen.</description>
    <arm_group_label>gestoden and ethinylestradiol</arm_group_label>
    <other_name>oral contraceptives</other_name>
    <other_name>quality of life</other_name>
    <other_name>gestodene and ethinyl estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinylestradiol 15 mcg</intervention_name>
    <description>ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen</description>
    <arm_group_label>gestoden and ethinylestradiol</arm_group_label>
    <other_name>gestodene and ethinyl estradiol</other_name>
    <other_name>quality of life</other_name>
    <other_name>oral contraceptives</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fertile women with indication of use of contraceptive pills

        Exclusion Criteria:

          -  Fertile women with any surgical contraceptive method

          -  Women in menopause

          -  Diseases the forbidden the use of the drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>joao MM Silva, PhD Student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Geral de Fortaleza</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Geral de Fortaleza</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60115290</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <last_update_submitted>August 2, 2010</last_update_submitted>
  <last_update_submitted_qc>August 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Joao Marcos de Meneses e Silva, MD, Public Health Master, PhD Student</name_title>
    <organization>Hospital Geral de Fortaleza</organization>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>Menopause</keyword>
  <keyword>Contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Gestodene</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Femovan</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

